4 news items
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
ADAP
31 May 24
a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
the potential for the delivery of fresh, fit cells with a vein-to-vein time of seven days in a patient population in which rapid access to treatment
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
days in a patient population in which rapid access to treatment is vital.Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "Data
Garry Menzel joins GHO Capital as Operating Partner
ADAP
BDTX
DVA
23 Apr 24
on achieving better, faster and more accessible healthcare is a central ethos that we share. I look forward to working with their incredible portfolio
- Prev
- 1
- Next